Hematologic Neoplasms Clinical Trial
Official title:
Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea and vomiting (CINV) in hematology patients receiving highly or moderately emetogenic chemotherapy regimens.
Nausea and vomiting remains a common and difficult to manage consequence of chemotherapy
despite prophylaxis. These symptoms can often lead to a decreased quality of life,
dehydration, and malnutrition. Olanzapine is an atypical antipsychotic that blocks multiple
neuronal receptors involved in nausea/vomiting pathways. Olanzapine has been studied for
breakthrough chemo-induced nausea and vomiting (CINV) as well as in prophylaxis of highly and
moderately emetogenic regimens (HEC and MEC, respectively). However, these studies have
focused on patients with solid tumor malignancies and chemotherapy regimens of short
duration. To date, no publications have reported outcomes from adding olanzapine to standard
triplet therapy, for hematology patients, including those undergoing hematopoietic stem cell
transplants and those who receive multi-day HEC and MEC regimens.
This is a blinded, placebo controlled trial randomizing patients to receive olanzapine 10 mg
orally on all chemotherapy days plus three additional days post chemotherapy or placebo in
addition to standard triplet therapy (ondansetron and dexamethasone on each day of
chemotherapy and fosaprepitant 150 mg IV on day one of chemotherapy). Inclusion criteria: age
18 or older, receiving inpatient or outpatient HEC or MEC chemotherapy including those
regimens given before stem cell transplantation (ABVD, ICE ± R, 7+3 or 5+2, BEAM, Bu/Cy ±
ATG, Bu/Flu ± ATG, FluCy ± ATG, BuMel, FluBuCy, Melphalan). Exclusion criteria: allergy to
olanzapine, documented nausea/vomiting ≤24 hours before enrollment, treatment with other
antipsychotic agents, or declined informed consent. Patients will be randomized to placebo or
olanzapine in a block design stratified by chemotherapy type (transplant conditioning vs.
chemotherapy only) and number of days of chemotherapy (single vs. multi-day) by the
Investigational Drug Pharmacy services at Augusta University Medical Center.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03483194 -
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03735992 -
Mind-body Medicine for Patients With Malignant Hematological Diseases
|
N/A | |
Recruiting |
NCT04959175 -
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04275154 -
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
|
||
Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
Completed |
NCT00389428 -
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
|
Phase 1 | |
Completed |
NCT02193880 -
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
|
N/A | |
Recruiting |
NCT00071045 -
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
|
||
Not yet recruiting |
NCT05054231 -
Immunological Profile for Patients Treated With CAR-T Cells
|
N/A | |
Completed |
NCT02650791 -
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
|
Phase 3 | |
Completed |
NCT01362179 -
National Marrow Donor Program Long-Term Donor Follow-Up
|
||
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Terminated |
NCT03648372 -
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
|
Phase 1/Phase 2 | |
Recruiting |
NCT03320915 -
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT
|
Phase 2 | |
Recruiting |
NCT06422533 -
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients
|
N/A | |
Terminated |
NCT02895529 -
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
|
Phase 4 | |
Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT03083327 -
Prophylactic Early PN in HPT/BMT
|
N/A | |
Recruiting |
NCT03743480 -
Early Palliative Care and Hematological Cancer Patients
|
N/A |